Stanley J. Goldsmith, M.D.
Stanley J. Goldsmith, M.D. has been Professor of Radiology and Professor of Medicine at the Weill Medical College of Cornell University since 1995. He served as Division Chief of Nuclear Medicine, Department of Radiology at The NewYork-Presbyterian Hospital /Weill Cornell Campus and from 1995 through 2012. Prior to these appointments, from 1992-95, Dr. Goldsmith was the Clinical Director of the Nuclear Medicine Service, Attending Radiologist and Member at the Memorial Sloan-Kettering Cancer Center in New York and Professor of Radiology at the Cornell University Medical College. From 1973-92, he was the Director of the Department of Physics-Nuclear Medicine at the Mount Sinai Medical Center in New York and from 1969-73, he was the Director of Nuclear Medicine at the Nassau County Medical Center.
Dr. Goldsmith was President of the Society of Nuclear Medicine in 1985-86 and Editor-in-Chief of the Journal of Nuclear Medicine from 1994-1999. He is the editor of the textbook Nuclear Oncology, which was published by Lippincott W & W in 2000, and currently serves on the Editorial Boards of the Journal of Nuclear Medicine, and Cancer Biotherapy & Radiopharmaceuticals. He was a Director of the American Board of Nuclear Medicine from 1990-1996 and served as Treasurer of the Board from 1995-96. Dr. Goldsmith served as a Commissioner on the New York State Low Level Radioactive Materials Siting Commission for 8 years, from 1987 through 1995 and had earlier served as a member of the Radioactive Drug Advisory Committee of the Food and Drug Administration and has been a consultant to the Nuclear Regulatory Commission on issues relating to public perception. He has served as Chairman of Committees and Councils of the Society of Nuclear Medicine including the Government Relations Committee, the Joint SNM-ACNP Government Oversight Committee, the Radioassay Council and recently completed a 2 year term as President of the Therapy Council of the Society of Nuclear Medicine. Dr. Goldsmith served as Chairman of the Nuclear Medicine Section of the New York Academy of Medicine through April 2006.
Dr. Goldsmith has received numerous awards, including the Distinguished Educator Award from the Society of Nuclear Medicine and Excellence as a Teacher in Radiology from his alma mater the State University of New York Downstate College of Medicine. He recently received the DeWitt Clinton Award from the NY State Masonic Lodge, the highest honor presented to a non-Mason. He has been named in the Best Doctors in New York and Best Doctors in America publications for several years and has appeared in Who's Who in America for over a decade. Dr. Goldsmith is the author of approximately 150 scientific articles, 21 book chapters, 27 invited articles and reviews and over 250 scientific abstracts.
Dr. Goldsmith completed his undergraduate education at Columbia College, Columbia University and was awarded the B.A. degree in 1958. He received his M.D. degree from the SUNY Downstate Medical Center in 1962. Subsequently, he was an intern on the University Service of Kings County Hospital and was a resident and Chief Resident in Internal Medicine at Kings County and the SUNY University Hospital, chaired by Ludwig Eichna, M.D. He was a United States Public Health Service (USPHS) Fellow in Medicine [Endocrinology] at the Mount Sinai Hospital under the supervision of Louis Soffer, M.D. and a Research Associate of Dr. Roslyn Yalow and Dr. Solomon Berson at the Veterans Administration Hospital in the Bronx. He achieved Board Certification in Nuclear Medicine from the American Board of Nuclear Medicine and in Internal Medicine from the American Board on Internal Medicine. Dr. Goldsmith served our nation as a Captain in the United States Army Medical Corps on active duty in Germany from 1963-1965.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.
- AETNA [HMO]
- AETNA [Medicare]
- AETNA [PPO]
- Aetna - Weill Cornell [POS]
- Affinity Health Plan
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [HMO]
- Fidelis Care
- GHI [CBP]
- Health First
- Health Insurance Plan of NY (HIP)
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Plus - Amerigroup
- Medicare [Medicare]
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Freedom]
- Oxford Health Plans [Medicare Advantage]
- Rockefeller University - CoreSource
- United Empire
- United Health Care [Community Plan]
- United Health Care
- United Health Care [Medicare]
1. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Research. 2000; 60: 5237 - 5243.
2. Kostakoglu L, Goldsmith SJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?
Eur J Nucl Med 2000; 27:1564-1578.
3. Kostakoglu L, Goldsmith SJ: Positron Emission Tomography in Lymphoma: Comparison with computed tomography and Gallium-67 Single Photon Emission Computed Tomography Clinical Lymphoma 2000; 1: 67-74
4. Kostakoglu L, Goldsmith SJ: Imaging multidrug resistance in hematological malignancies
Hematology 2001; 6: 111-124
5. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ: Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94:879-888.
6. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ: Positron emission tomography [PET] predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and HodgkinÂs disease. J Nucl Med 2002; 43: 1018-1027
7. Kostakoglu L, Goldsmith SJ: 18F-FDG-PET Evaluation of response to therapy for lymphoma and for breast, lung and colorectal carcinoma. J Nucl Med 2003; 44: 224-239
8. Kostakoglu L, Agress H, Goldsmith SJ: Clinical Role of FDG-PET in the evaluation of cancer patients. Radiographics 2003; 22: 315-340
9. Leonard JP, Siegel JA, Goldsmith SJ: Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with nonHodgkinÂs Lymphoma. Cancer Investigation 2003; 21: 241-252
10. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S,
Goldsmith SJ, Bander NH. Clinical use of monoclonal antibody HuJ591 therapy:
targeting prostate specific membrane antigen. J Urology 2003; S88-98
11. Bander NH. Nanus DM. Milowsky MI. Kostakoglu L. Vallabahajosula S. Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Sem Oncol 2003; 30:667-76
12. Bander NH, Trabuli EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P,
Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urology 2003; 170:1717-21
13. Smith-Jones PM. Vallabhajosula S. Navarro V. Bastidas D. Goldsmith SJ. Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44:610-617
14. Vallabhajosula S. Smith-Jones PM. Navarro V. Goldsmith SJ. Bander NH.
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal
antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 2004; 58:145-55
15. Kostakoglu L. Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med: 2004; 45: 56-68
16. Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ: The role of FDG-PET Imaging in the management of lymphoma. Clin Advances in Hem & Onc 2004; 2:115-121
17. Vallabajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J Nucl Med. 2005; 46: 634-41
1. Goldsmith SJ, Kostakoglu L: Role of Nuclear Medicine in the Evaluation of the Solitary Pulmonary Nodule Seminars in Ultrasound, CT and MRI 2000; 21: 129-138
2. Goldsmith SJ, Kostakoglu L: Nuclear Medicine Imaging of Lung Cancer
Radiologic Clinics of North America 2000; 38: 511-524
3. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ. Procedure Guideline for Somatostatin receptor scintigraphy with 111In-pentetreotide J Nucl Med 2001; 42: 1134-1138
4. Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Sem Nucl Med 2001; 31:177-190.
5. Goldsmith SJ: Status of Radiolabeled Peptides in Diagnosis and Therapy Sem Nucl Med 2002; 32: 78 [Guest Editorial]
6. Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith SJ: The utility of monoclonal antibodies in the imaging of prostate cancer. Sem Urol Onc 2002; 20:211-218
7. Goldsmith SJ, Kostakoglu L, Somrov S, Palestro C: Radionuclide Imaging of Thoracic Malignancies. Chest Surgery Clinics of North America 2004; 14: 95-
8. Goldsmith SJ. Improving Insight into Radiobiology and Radionuclide Therapy. J Nucl Med 2004; 45: 1104-1105
9. Goldsmith SJ, Kostakoglu L, Somrov S, Palestro C: Radionuclide Imaging of Thoracic Malignancies. Radiologic Clinics of North America 2005; 43: 571-588
1. Goldsmith SJ. Thyroid Carcinoma: Diagnosis, Management and Therapy, pgs 197 - 220 in Khalkhali I, Maublant J, Goldsmith SJ [Ed]: Nuclear Oncology: Diagnosis and Therapy, Lippincott Williams & Wilkins (Philadelphia), 2000
2. Goldsmith SJ, Bander N: Prostate Carcinoma: Therapy with Radiolabelled Monoclonal Antibodies, pgs 433 - 440 in Khalkhali I, Maublant J, Goldsmith SJ [Ed]: Nuclear Oncology: Diagnosis and Therapy, Lippincott Williams & Wilkins (Philadelphia), 2000
3. Goldsmith SJ. Nuclear Oncology: An Overview, pgs 1 - 12 in Khalkhali I, Maublant J, Goldsmith SJ [Ed]: Nuclear Oncology: Diagnosis and Therapy, Lippincott Williams & Wilkins (Philadelphia), 2000
4. Goldsmith SJ, Kostakoglu L. Nuclear Medicine in the Diagnosis and Management of Colorectal Cancer, pgs 157-177 in Saltz L [Ed]: Colorectal Cancer: Multimodality Management, Humana Press (Totowa, NJ), 2002
5. Goldsmith SJ, Bar-Shalom R, Kostakoglu L, Weiner R, Neumann R: Gallium-67 Scintigraphy in Tumor Detection, pgs 911-929 in Sandler M, Coleman R e al [eds] Diagnostic Nuclear Medicine, Lippincott Williams and Wilkins (Philadelphia) 2003
6. Kostakoglu L, Goldsmith SJ: Staging and Followup of Lymphoma with [F-18]Fluorodeoxyglucose PET and Gallium-67 Imaging, pgs 29-74, in Freeman, L [ed] Nuclear Medicine Annual 2003, Lippincott Williams & Wilkins (Philadelphia) 2003
7. Goldsmith SJ. The Endocrine System, pgs 350-385 in Bernier DR, Christian PE, Langan JK: Nuclear Medicine and PET: Technology and Techniques, 5th edition, Mosby (St. Louis), 2003
- Nuclear Medicine
- Nuclear Medicine
- Nuclear Cardiology
- Thyroid Disorder
- Thyroid Disease
Contact and Practices
- Nuclear Medicine
- Internal Medicine
- Nuclear Medicine
- M.D., State University of New York Health Science Center at Brooklyn, 1962